European Commission finalizes joint clinical assessment rules for member countries

The Eu­ro­pean Com­mis­sion on Thurs­day fi­nal­ized rules on how it pools ex­per­tise from across the EU to as­sess the ef­fec­tive­ness of new drugs when com­pared to drugs al­ready on the mar­ket. The rules are part of a broad­er ini­tia­tive to bol­ster col­lab­o­ra­tion across the con­ti­nent for eval­u­at­ing and pay­ing for new prod­ucts.

Un­der the cur­rent frame­work, new health tech­nolo­gies un­der­go na­tion­al-lev­el as­sess­ments to de­ter­mine their cost-ef­fec­tive­ness, which can be ex­pen­sive and time-con­sum­ing. The new rules set time­lines and con­crete steps that mem­ber coun­tries should fol­low when con­duct­ing joint as­sess­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.